ESSEXBIO-TECH：ANNUALREPORT2022.pdf

1、年報ANNUAL REPORT 2022 ANNUAL REPORT 年報20222022 SCIENCE&TECHNOLOGYPIONEERING GLOBALREGENERATIVETODAYTOMORROWSAnnual Report 20221CONTENTS CONTENTS2Chairmans Statement10Business Review20Financial Highlights21Financial Review28Profles of Directors and Senior Management31Report of the Directors53Independe

2、nt Auditors Report57Consolidated Statement of Proft or Loss and Other Comprehensive Income58Consolidated Statement of Financial Position59Consolidated Statement of Changes in Equity60Consolidated Statement of Cash Flows62Notes to the Consolidated Financial Statements132Five Year Financial Summary133

3、Corporate Governance Report146Corporate InformationContentsNgiam Mia Je PatrickChairmanESSEX BIO-TECHNOLOGY LIMITED2 CHAIRMANS STATEMENTCHAIRMANS STATEMENTAnnual Report 20223 CHAIRMANS STATEMENTDuring the year under review,the financial results of Essex Bio-Technology Limited(the“Company”,together w

4、ith its subsidiaries,the“Group”)have been negatively impacted,and ongoing clinical trial programmes have been delayed due to disruptions resulting from sporadic emergence and persistent spread of COVID-19 in most parts of 2022 and the ensuing lockdowns instituted under the“zero-COVID policy”in the P

5、eoples Republic of China(the“PRC”).Despite yet another difficult year inflicted by the pandemic of COVID-19 on us all,the tenacity,drive and leadership in our DNA were able to deliver sustained stakeholder value.FINANCIAL PERFORMANCEFor the year ended 31 December 2022,the Group achieved a consolidat

6、ed turnover of approximately HK$1,317.7 million,with a decrease of 19.5%as compared to approximately HK$1,637.7 million in 2021.Correspondingly,the Groups profit decreased by 34.8%to approximately HK$225.4 million as compared to approximately HK$346.0 million in 2021.The Groups profit was weighed do